Dynavax Technologies (DVAX) Research & Development (2016 - 2025)
Historic Research & Development for Dynavax Technologies (DVAX) over the last 17 years, with Q3 2025 value amounting to $19.1 million.
- Dynavax Technologies' Research & Development rose 3272.23% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.8 million, marking a year-over-year increase of 2944.04%. This contributed to the annual value of $61.6 million for FY2024, which is 1214.15% up from last year.
- Latest data reveals that Dynavax Technologies reported Research & Development of $19.1 million as of Q3 2025, which was up 3272.23% from $16.6 million recorded in Q2 2025.
- In the past 5 years, Dynavax Technologies' Research & Development registered a high of $19.4 million during Q1 2025, and its lowest value of $6.2 million during Q3 2021.
- In the last 5 years, Dynavax Technologies' Research & Development had a median value of $13.5 million in 2024 and averaged $13.2 million.
- As far as peak fluctuations go, Dynavax Technologies' Research & Development plummeted by 2740.29% in 2021, and later skyrocketed by 10953.77% in 2022.
- Over the past 5 years, Dynavax Technologies' Research & Development (Quarter) stood at $11.1 million in 2021, then rose by 15.62% to $12.9 million in 2022, then increased by 9.84% to $14.1 million in 2023, then surged by 32.23% to $18.7 million in 2024, then grew by 2.39% to $19.1 million in 2025.
- Its Research & Development was $19.1 million in Q3 2025, compared to $16.6 million in Q2 2025 and $19.4 million in Q1 2025.